LOS ANGELES (Reuters) - Genentech Inc said on Thursday it will ban on November 30 direct purchases of Avastin by independent compounding pharmacies, which repackage the cancer drug as a low-cost substitute for its newer eye drug, Lucentis.Avastin is chemically similar to Lucentis, Genentech’s approved drug for treating wet, age-related macular degeneration, a condition in which bleeding under the retina harms vision.
